Anti-MAP3K14 Polyclonal Antibody
The Anti-MAP3K14 Polyclonal Antibody is a highly specific and sensitive tool for the detection of MAP3K14 protein in various biological samples. This antibody is produced by immunizing rabbits with a synthetic peptide corresponding to a region within the C-terminal domain of human MAP3K14.
MAP3K14, also known as Mitogen-activated protein kinase kinase kinase 14, is a key regulator of the MAPK signaling pathway. This pathway plays a crucial role in various cellular processes such as cell growth, differentiation, and survival. MAP3K14 is involved in the activation of the JNK and p38 MAPKs, which are important mediators of stress and inflammatory responses.
The Anti-MAP3K14 Polyclonal Antibody is widely used in research studies to investigate the role of MAP3K14 in different biological processes. It is particularly useful in studies related to cancer, as MAP3K14 has been found to be overexpressed in various types of cancer and is associated with tumor growth and progression.
This antibody is suitable for use in various applications, including Western blotting, immunoprecipitation, and immunofluorescence. It has been validated for use in human, mouse, and rat samples, making it a versatile tool for researchers working with different model systems.
In addition to its use in basic research, the Anti-MAP3K14 Polyclonal Antibody has potential applications in drug discovery and development. As MAP3K14 is a potential target for cancer therapy, this antibody can aid in the identification and validation of novel drug candidates.
In summary, the Anti-MAP3K14 Polyclonal Antibody is a reliable and specific tool for the detection of MAP3K14 protein. Its high sensitivity and versatility make it a valuable asset for researchers studying the role of MAP3K14 in various biological processes and for those involved in drug discovery. Trust in the quality and performance of this antibody to advance your research goals. Order now to take the first step towards groundbreaking discoveries.
There are no reviews yet.